Nd T2d Oad Selector

---
name: nd-t2d-oad-selector
description: Select oral and injectable glucose-lowering agents for a newly diagnosed patient with type 2 diabetes using a compelling-indication hierarchy (heart failure → ASCVD → DKD → obesity) followed by glucose-pattern matching. Incorporates modern GLP-1 receptor agonists — Ozempic (semaglutide SC, T2D), Mounjaro (tirzepatide), and Wegovy/Noveltreat (semaglutide 2.4 mg, obesity). Use when a clinician asks "what drug to start for newly diagnosed T2D", "which OAD to use", "first-line diabetes medication", "SGLT2i vs GLP-1 in new T2D", or presents a newly diagnosed T2D patient needing a personalised medication plan.
---

# OAD Selection — Newly Diagnosed Type 2 Diabetes

## Confirm Eligibility First

This tool is for newly diagnosed, **non-insulin-requiring** T2DM.  
Stop here and initiate insulin instead if any of the following apply:

- HbA1c ≥10%
- Any glucose >400 mg/dL
- FBS >200 AND PP2BS ≥300 mg/dL
- Osmotic symptoms (polyuria, polydipsia, weight loss) or ketosis
- GAD antibody positive, OR random C-peptide <0.6 ng/mL with glucose 70–300 mg/dL

Also excluded: pregnancy, age <18, glucocorticoid-induced hyperglycaemia, eGFR <30.

---

## Step 1 — Metformin (Universal First Line)

**Tab Metformin SR/ER 1 g OD after breakfast**

Skip only if: eGFR <30.

> Always co-prescribe **Methylcobalamin 1000 mcg OD** after lunch with metformin.

Expected HbA1c reduction: ~0.8%

---

## Step 2 — Compelling Indication Hierarchy

Work through A → D in order. Stop at the first that applies and add the indicated drug.

---

### A. Heart Failure

→ Add an **SGLT2 inhibitor** (proven HF mortality benefit)

| Drug | Dose | Trial |
|------|------|-------|
| Empagliflozin | 25 mg OD morning | EMPEROR-Reduced/Preserved |
| Dapagliflozin | 10 mg OD morning | DAPA-HF |

---

### B. Established ASCVD or High CV Risk

*High CV risk = age >55 with ≥2 of: hypertension, overweight/obesity, smoking, LDL ≥100 mg/dL, UACR >30 mg/g*

**If open to injectable → GLP-1 RA first (proven CV benefit):**

| Drug | Starting dose | Titration | Max | Trial |
|------|--------------|-----------|-----|-------|
| Ozempic (semaglutide SC) | 0.25 mg SC weekly × 4 wk | → 0.5 mg × 4 wk | → 1 mg weekly | SUSTAIN-6 |
| Dulaglutide | 0.75 mg SC weekly | Fixed | 1.5 mg weekly | REWIND |

**If not open to injectable → SGLT2 inhibitor:**
- Empagliflozin 25 mg OD or Dapagliflozin 10 mg OD

**If both GLP-1 RA and SGLT2i contraindicated:**
- Pioglitazone 15 mg OD evening (PROACTIVE — CV benefit signal in T2D)
- *Skip if: heart failure, BMI >27, macular oedema, retinopathy not assessed*

---

### C. Diabetic Kidney Disease (eGFR <60 or UACR >30 mg/g)

→ **SGLT2 inhibitor first** (proven renal benefit):
- Dapagliflozin 10 mg OD (DAPA-CKD)
- Empagliflozin 10 mg OD (EMPA-KIDNEY)

**If SGLT2i contraindicated:**
- Ozempic (semaglutide SC) 0.25 → 0.5 → 1 mg SC weekly (FLOW trial — renal benefit)

---

### D. Obesity (BMI ≥30, or BMI ≥27 with ≥1 comorbidity)

Rank by degree of weight loss needed and injectable preference:

| Choice | Drug | Starting dose | Titration to maintenance |
|--------|------|--------------|--------------------------|
| 1st — best glucose + weight | **Mounjaro (tirzepatide)** | 2.5 mg SC weekly | ↑ 2.5 mg every ≥4 wk → max **15 mg** |
| 2nd — strong weight + glucose | **Wegovy / Noveltreat (semaglutide 2.4 mg)** | 0.25 mg SC weekly | → 0.5 → 1 → 1.7 → **2.4 mg** (every 4 wk) |
| 3rd — not open to injectable | **Dapagliflozin 10 mg** or **Canagliflozin 300 mg** OD | — | — |

> **12-week continuation rule (Wegovy/Noveltreat):** reassess at week 12 on maintenance dose. Discontinue if no meaningful BMI improvement.

> **Mounjaro 2.5 mg note:** initiation dose only — not for glycaemic control. First therapeutic dose is 5 mg.

---

## Step 3 — Still Above HbA1c Target? Match the Glucose Pattern

Calculate: **Delta = PP2BS − FBS (mg/dL)**

### Delta >60 → Post-meal predominant

| Preference | Drug | Dose |
|-----------|------|------|
| Open to multiple pills | Acarbose | 50 mg TDS immediately before meals |
| Not open to multiple pills | Sitagliptin | 100 mg OD after breakfast |
| AGI contraindicated + open to pills | Repaglinide | 0.5 mg TDS immediately before meals |

> ⚠️ Do NOT add a DPP-IV inhibitor if already on a GLP-1 RA — redundant mechanisms, no additive benefit.

> ⚠️ Saxagliptin + heart failure — avoid. Use Sitagliptin instead.

> Alpha-glucosidase inhibitors (acarbose) contraindicated if eGFR <25.

### Delta ≤60 → Fasting predominant

| Drug | Dose | Note |
|------|------|------|
| Gliclazide XR *(preferred)* | 60 mg OD, 30 min after breakfast | Lower hypo risk than glimiperide |
| Glimiperide | 1 mg OD, 30 min after breakfast | Alternative |

*Sulphonylurea contraindicated if: eGFR <15, moderate-to-severe frailty*

If SU contraindicated → **Pioglitazone 15 mg OD** evening *(if not already given)*

If pioglitazone also contraindicated → **Add Basal Insulin:**
- Degludec at 10 pm (flexible timing — preferred for shift workers)
- Glargine at 10 pm (fixed timing)
- NPH at 10 pm (budget)

Starting dose: **(FBS − 50) ÷ 10 units**

---

## Step 4 — Neuropathy Add-ons

**All patients on metformin** → Methylcobalamin 1000 mcg OD (already covered in Step 1).

**If painful diabetic peripheral neuropathy is present, add:**
- Pregabalin SR 75 mg at 7–8 pm (1–2 h before bedtime)
- Plus, if no ASCVD + BMI normal: **Duloxetine 20 mg at bedtime** (titrate to 60–120 mg)
- If ASCVD present or BMI >30: **Alpha Lipoic Acid 600 mg OD** after lunch (use instead of Duloxetine)

---

## GLP-1 RA Contraindications (all agents)

- Personal or family history of MTC or MEN-2
- Pancreatitis history *(absolute for Noveltreat; strong caution for Ozempic/Mounjaro)*
- Severe gastroparesis
- BMI <19 (underweight)
- Pregnancy
- Do not combine with another GLP-1 RA or DPP-IV inhibitor

## SGLT2i Contraindications

- eGFR <25
- Ketosis or osmotic symptoms at presentation
- Active genitourinary infection
- BMI <19
- Severe frailty

---

## Key Drug Interactions

| Combination | Action |
|------------|--------|
| GLP-1 RA + sulphonylurea | Reduce SU dose at initiation → `glp1-insulin-su-dose-reduction` |
| GLP-1 RA + basal insulin | Reduce insulin by ~20% at initiation |
| Mounjaro + oral contraceptive | Non-oral or barrier contraception for 4 wk after each dose step → `glp1-oral-contraceptive-interaction` |
| DPP-IV + GLP-1 RA | Avoid — stop DPP-IV when adding GLP-1 RA |

---

## Clinical Guardrails

- **Ozempic vs Wegovy/Noveltreat** — same molecule (semaglutide), different indication and max dose. Ozempic = T2D glycaemic control, max **1 mg** weekly. Wegovy/Noveltreat = obesity, max **2.4 mg** weekly. Never co-prescribe.
- **Mounjaro 2.5 mg** = tolerability dose, not a therapeutic dose. Expect glycaemic benefit from 5 mg onwards.
- **Retinopathy + pioglitazone** — always assess retinal status before prescribing; can worsen macular oedema.
- **Perioperative GLP-1 RA** — hold before procedures under GA/sedation. See `glp1-perioperative-aspiration`.

---

## Cross-Reference Skills

| Need | Skill |
|------|-------|
| GI side-effect management | `glp1-gi-ae-symptom-advisor`, `glp1-dose-escalation-troubleshooter` |
| Pancreatobiliary monitoring | `glp1-pancreatobiliary-risk-monitor` |
| Perioperative decisions | `glp1-perioperative-aspiration` |
| SU/insulin dose reduction | `glp1-insulin-su-dose-reduction` |
| Mounjaro full prescribing | `mounjaro-prescribing-guide` |
| Wegovy/Noveltreat prescribing | `wegovy-prescribing-guide`, `noveltreat-prescribing-guide` |
| DKD staging | `nd-t2d-dkd-classifier` *(coming)* |
| HbA1c target | `nd-t2d-hba1c-target` *(coming)* |

---

## Source

Diabetology.co.in Newly Diagnosed T2DM Algorithm (Lakhani O). Evidence base: ADA Standards of Care 2024; EMPA-REG OUTCOME, EMPEROR; DAPA-HF, DAPA-CKD; EMPA-KIDNEY; SUSTAIN-6; FLOW; REWIND; SURPASS 1–5; STEP 1–4; SURMOUNT 1–4.